Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

189.43 +1.19 (+0.63%)
Streaming Delayed Price Updated: 12:28 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
57 58 Next >
News headline image
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
(BIIB) - Analyzing Biogen's Short Interest ↗
 
Via Benzinga
News headline image
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment ↗
The company is now focusing on its launch in postpartum depression. 
Via Investor's Business Daily
News headline image
The 7 Most Promising Momentum Stocks to Own Now ↗
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
News headline image
The 3 Most Promising Pharma Stocks to Own Now ↗
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
News headline image
Analyst Ratings for Biogen ↗
 
Via Benzinga
News headline image
Better Buy: Biogen vs. Eli Lilly ↗
This battle of biotech giants has a clear winner. 
Via The Motley Fool
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗
 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
News headline image
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock ↗
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5% 
Via InvestorPlace
News headline image
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? ↗
The pharmaceutical company's growth prospects have taken a big hit. 
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Is Sage Therapeutics a Contrarian Buy? ↗
A regulatory setback weighed heavily on the drugmaker's shares Monday. 
Via The Motley Fool
News headline image
Biogen Unusual Options Activity For August 02 ↗
 
Via Benzinga
News headline image
Why Shares of Sage Therapeutics Slumped This Week ↗
The company got bad news from the FDA and saw increased losses. 
Via The Motley Fool
News headline image
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around? ↗
The company's rare disease portfolio may soon get an upgrade. 
Via The Motley Fool
News headline image
With an Acquisition on the Way, Is Biogen Stock a Buy? ↗
Can the biotech finally get back in the good graces of investors? 
Via The Motley Fool
News headline image
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? ↗
Lilly shares surged 15% in one day to a record high. Here's what you should know. 
Via Investor's Business Daily
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
News headline image
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead ↗
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter 
Via Benzinga
News headline image
Dow Rises Over 300 Points To Start The Week ↗
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses. 
Via Talk Markets
News headline image
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
News headline image
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug ↗
The company gained approval for the first oral treatment for postpartum depression. 
Via Investor's Business Daily
News headline image
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another ↗
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with  
Via Benzinga
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.